US Stock MarketDetailed Quotes
VYNE VYNE Therapeutics
- 2.9700
- +0.4000+15.56%
Close Dec 24 13:00 ET
- 2.9100
- -0.0600-2.02%
Post 17:01 ET
43.81MMarket Cap0.88P/E (TTM)
3.0744High2.5300Low179.86KVolume2.5600Open2.5700Pre Close514.74KTurnover1.74%Turnover RatioLossP/E (Static)14.75MShares3.430052wk High0.69P/B30.72MFloat Cap1.570052wk Low--Dividend TTM10.34MShs Float2869.9200Historical High--Div YieldTTM21.18%Amplitude1.5700Historical Low2.8610Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
VYNE Therapeutics Stock Forum
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
VYNE Therapeutics announced positive results from the multiple ascending dose (MAD) portion of its Phase 1a trial for VYN202, a novel BD2-selective BET inhibitor. The study demonstrated a favorable safety and tolerability profilewith no serious adverse events or drug-related issues historically associated with earlier BET inhibitors.
Key findings includ...
Vyne Therapeutics Reports Positive Top-Line Phase 1a Mad Data for Vyn202, Its Novel BD2-Selective Bet Inhibitor
Vyne Therapeutics Inc: Positive Phase 1a Sad Data for Vyn202, a Novel BD2-Selective Bet Inhibitor! well tolerated. No adverse events
Upcoming Conference Participation
•H.C. Wainwright 26th Annual Global Investment Conference, September 9-11, 2024, New York, NY
•Stifel Immunology and Inflammation Virtual Summit, September 17-18, 2024
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
Vyne Therapeutics Announces FDA Clearance of Ind Application for Vyn202, a Novel Bd2-Selective Bet Inhibitor
NEWS
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
No comment yet